会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • A PROCESS AND EXTRACTANT COMPOSITION FOR EXTRACTING ACIDS
    • 用于提取酸的方法和提取物组合物
    • WO1995025081A1
    • 1995-09-21
    • PCT/GB1995000535
    • 1995-03-13
    • YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMWHALLEY, KevinEYAL, Aharon, Meir
    • YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMWHALLEY, Kevin
    • C07C51/48
    • C07C51/48
    • The invention provides a process for the recovery of a water-soluble carboxylic or mineral acid having a pKa higher than 2 from an aqueous feed solution containing the acid or a salt thereof, comprising extracting the acid with a water-immiscible extractant composition, the composition comprising: (a) at least one secondary or tertiary alkyl amine, in which the aggregate number of carbon atoms is at least 20, as a primary extractant; and (b) a sterically hindered, polar, organic compound having at least 5 carbon atoms, a basicity weaker than that of the primary extractant, and temperature-sensitive, extraction-modifying properties; separating the acid containing the extractant and subjecting it to a stripping operation at a temperature of at least 20 DEG C higher than the temperature at which the extraction is carried out, wherein the sterically hindered, polar, organic compound both modifies the extracting power of the primary extractant composition and facilitates the temperature-sensitive stripping operation. The invention also provides an extractant composition for use in such a process.
    • 本发明提供一种从含有酸或其盐的含水进料溶液中回收具有高于2的pKa的水溶性羧酸或无机酸的方法,包括用水不混溶的萃取剂组合物萃取酸,该组合物 包括:(a)至少一种其中总碳原子数为20以上的仲或叔烷基胺作为主要提取剂; 和(b)具有至少5个碳原子的空间位阻极性有机化合物,其碱性弱于初级萃取剂,碱度低于温度敏感性,萃取 - 改性性质; 分离含有萃取剂的酸,并在比进行萃取的温度高至少20℃的温度下进行汽提操作,其中空间位阻极性有机化合物改变了萃取剂的萃取力 初级萃取剂组合物,并有助于温度敏感的汽提操作。 本发明还提供了用于这种方法的萃取剂组合物。
    • 10. 发明申请
    • SYNTHETIC ANTISENSE OLIGODEOXYNUCLEOTIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    • 合成抗体寡糖氧化酶和含有它们的药物组合物
    • WO1998026062A2
    • 1998-06-18
    • PCT/US1997023598
    • 1997-12-12
    • YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMKOHN, Kenneth, I.SOREQ, HermonaSEIDMAN, ShlomoECKSTEIN, FritzFRIEDMAN, AlonKAUFER, Daniela
    • YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMKOHN, Kenneth, I.
    • C12N15/00
    • C12Y301/01007A01K2217/05A61K38/00C12N15/1137C12N2310/315C12N2310/321C12N2310/322C12N2310/53C12N2310/3521
    • A synthetic nuclease resistant antisense oligodeoxynucleotide (AS-ODN) capable of selectively modulating human acetylcholinesterase (AChE) production and a pharmaceutical or medical composition comprising at least one AD-ODN as an active ingredient. In an embodiment the AS-ODN can be selected from 5'ACGCTTTCTTGAGGC 3' (SEQ ID NO.1), 5'GGCACCCTGGGCAGC 3' (SEQ ID NO.2); 5'CCACGTCCTCCTGCACCGTC 3' (SEQ ID NO.6); 5'ATGAACTCGATCTCGTAGCC 3' (SEQ ID NO.7); 5'GCCAGAGGAGGAGGAGAAGG 3' (SEQ ID NO.4); 5'TAGCGTCTACCACCCCTGAC 3' (SEQ ID NO.5), 5'TCTGTGTTATAGCCCAGCCC 3' (SEQ ID NO.17); and 5'GGCCTGTAACAGTTTATTT 3' (SEQ ID NO.18). A nuclease resistant antisense targeted against the splice junction in the AChEmRNA post splice message is disclosed. In an embodiment, a nuclease resistant AS-ODN targeted against the E4-E6 junction in the E1-E4-E6 splice variant AChEmRNA is disclosed as being highly specific for the muscle and central nervous system splice variant of AChE. The synthetic nuclease resistant AS-ODNs are capable of selectively modulating human AChE production in the central nervous system or capable of selectively reducing human AChE deposition in the neuromuscular junction. The present invention also provides a method to restore balanced cholinergic signaling in the brain and spinal cord or reduce AChE in the neuromuscular junction in patients in need of such treatment comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one of the synthetic nuclease resistant AS-ODN capable of selectively modulating human AChE production.
    • 能够选择性调节人乙酰胆碱酯酶(AChE)生产的合成核酸酶抗性反义寡脱氧核苷酸(AS-ODN)和包含至少一种AD-​​ODN作为活性成分的药物或医药组合物。 在一个实施方案中,AS-ODN可以选自5'ACGCTTTCTTGAGGC 3'(SEQ ID NO.1),5'GGCACCCTGGGCAGC 3'(SEQ ID NO.2); 5'CCACGTCCTCCTGCACCGTC 3'(SEQ ID NO.6); 5'ATGAACTCGATCTCGTAGCC 3'(SEQ ID NO.7); 5'GCCAGAGGAGGAGGAGAAGG 3'(SEQ ID NO.4); 5'TAGCGTCTACCACCCCTGAC 3'(SEQ ID NO.5),5'TCTGTGTTATAGCCCAGCCC 3'(SEQ ID NO.17); 和5'GGCCTGTAACAGTTTATTT 3'(SEQ ID NO.18)。 公开了针对针对AChEmRNA后剪接消息中的剪接连接的核酸酶抗性反义。 在一个实施方案中,公开了针对E1-E4-E6剪接变体AChEmRNA中的E4-E6连接的核酸酶抗性AS-ODN作为AChE的肌肉和中枢神经系统剪接变体的高度特异性。 合成的核酸酶抗性AS-ODNs能够选择性调节中枢神经系统中的人AChE产生或能够选择性地降低神经肌肉接头中的人类AChE沉积。 本发明还提供一种在需要这种治疗的患者中恢复脑和脊髓中的平衡胆碱能信号传导或减少神经肌肉接头中的AChE的方法,包括向需要这种治疗的患者施用治疗有效量的至少一种 的能够选择性调节人AChE生产的合成核酸酶抗性AS-ODN。